Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Royalty Pharma plc

Get SEC filing alerts via email and in your feed for Royalty Pharma plc

RPRX

Royalty Pharma plc

About Royalty Pharma plc

Royalty Pharma plc is a leading investor in biopharmaceutical royalties, acquiring rights to revenue streams from marketed therapies and development-stage product candidates. Its diversified portfolio includes royalties on over 35 blockbuster drugs across various therapeutic areas, generating long-term cash flows. The company funds innovation through royalty acquisitions, partnering with industry stakeholders, and leveraging a capital-efficient model to drive growth and shareholder value.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Royalty Pharma plc

1
1
Royalty Pharma plc Royalty Pharma Reports 11% Income Growth to $630.6 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Royalty Pharma plc Royalty Pharma Reports $2.38 Billion Revenue for Fiscal Year 2025, Driven by Strategic Acquisitions

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Royalty Pharma plc Royalty Pharma Reports 7.9% Revenue Growth to $609.3 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Royalty Pharma plc Royalty Pharma Reports 7.7% Revenue Growth in Q2 2025, Completes Management Internalization

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Royalty Pharma plc Royalty Pharma Reports $238.3 Million Net Income in Q1 2025, Significant Year-Over-Year Increase

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Royalty Pharma plc Royalty Pharma Reports $2.8 Billion Revenue for Fiscal Year 2024, Down 3.9%

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Royalty Pharma plc Royalty Pharma Reports Strong Operating Income and Net Income, Expands Funding Collaboration and Makes Strategic Acquisitions

Via official filing (AI summary) | over 1 year ago | 0 comments